28/01/2025
Hans T. Scambye joins Sunstone as Venture Partner Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans...
08/01/2025
Neumirna Therapeutics secures euro 20M in Series A financing Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments